NEW YORK – Genomics plc and GSK announced on Tuesday a partnership to optimize clinical trial design by using polygenic risk scores (PRS) to better assess disease risk and select patients for those studies.

纽约——基因组学公司和葛兰素史克公司周二宣布合作，通过使用多基因风险评分（PRS）来优化临床试验设计，以更好地评估疾病风险并选择患者进行这些研究。

Through the partnership, the collaborators will examine how Genomics plc's suite of PRS tools might help improve the outcomes of both proof-of-concept and pivotal trials by reducing the number of trial particpants needed and shortening study times.

通过合作关系，合作者将研究基因组学公司的PRS工具套件如何通过减少所需的试验参与者数量和缩短研究时间来帮助改善概念验证和关键试验的结果。

Financial details of the partnership were not disclosed.

合伙企业的财务细节未披露。

'PRS-based approaches have the potential to support clinical trial design,' Peter Donnelly, founder and CEO of Genomics plc, said in a statement. 'Using PRS to get the right people into studies could have a potential positive impact, including in the reduction of trial size and timescale, leading to efficiencies in drug development.'.

基因组学公司创始人兼首席执行官彼得·唐纳利（PeterDonnelly）在一份声明中说，基于PRS的方法有可能支持临床试验设计使用PRS让正确的人参与研究可能会产生潜在的积极影响，包括减少试验规模和时间尺度，从而提高药物开发的效率。”。

Earlier this year, Genomics plc demonstrated the feasibility of implementing cardiovascular PRS into clinical settings. The UK-based company later published cross-ancestry scores for 10 chronic conditions, with plans to provide clinical utility data next year.

今年早些时候，Genomics plc证明了在临床环境中实施心血管PRS的可行性。这家总部位于英国的公司后来公布了10种慢性病的跨血统评分，并计划明年提供临床效用数据。